期刊文献+

蜂蜡素对HepG_2细胞HMG-CoA还原酶mRNA表达及蛋白质水平的影响 被引量:1

Effect of Fenglasu on the expression of HMG-CoA reductase mRNA and protein in HepG_2 cells
原文传递
导出
摘要 目的:探讨蜂蜡素对HepG2细胞HMG-CoA还原酶mRNA表达及蛋白质水平的影响。方法:采用MTT比色法,Western Blot,RT-PCR等技术方法,观察蜂蜡素对HepG2细胞存活能力、HMG-CoA还原酶mRNA表达及蛋白质水平的影响。结果:当蜂蜡素浓度为100mg·L-1或以下时,对细胞存活能力无影响,为本研究可选择的剂量范围;蜂蜡素处理HepG2细胞,随着蜂蜡素浓度升高(低、中、高浓度为0.8,8,80mg·L-1),HMG-CoA还原酶蛋白质水平和mRNA的表达均逐渐降低,呈现明显的浓度依赖关系。结论:蜂蜡素可抑制HepG2细胞HMG-CoA还原酶蛋白质及mRNA的表达。 Objective: To investigate the effect of Fenglasu on the expression of 3-hydroxy-3-methylglutaryl-eoenzyme A (HMG-CoA) reductase mRNA and protein in HepG2 cells. Methods: The cell proliferation was determined by MTT assay. The expression of HMG-CoA reductase mRNA and protein was determined by RT-PCR and Western blot. Results:As indicated by MTT assay, Fenglasu at 100 mg·L^-1 had no cytotoxicity in HepG2 cells, which provided the safe range for the following experiments. Both results of RT-PCR and Western blot showed that the mRNA and protein expression of HMG-CoA reductase gradually decreased with the increase of Fenglasu concentration (0.8, 8 and 80 mg·L^- 1 ). Conclusion : Fenglasu can inhibit the expression of HMG-CoA reductase mRNA and protein in HepG2 cells.
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第4期345-348,共4页 Chinese Journal of New Drugs
关键词 蜂蜡素 HEPG 细胞 HMG—CoA还原酶 mRNA 蛋白质 Fenglasu HepG2 cells 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase mRNA protein
  • 相关文献

参考文献12

  • 1廖芳,张小娜.新型降胆固醇药物蜂蜡素胶囊[J].中国药师,2005,8(12):1039-1040. 被引量:9
  • 2TEUPSER D, BRUEGEL M, STEIN O, etal. HMG-CoAreductase inhibitors reduce adhesion of human monocytes to endothelial cells[J]. Biochem Biophys Res Commun, 2001, 289(4) :838 - 844.
  • 3刘斌,王为.细胞培养[M].西安:世界图书出版西安公司,2005:235-257
  • 4Choice of lipid-regulating drugs[ J ]. Med Lett Drugs Ther, 2001, 43(1105): 43-48.
  • 5KNOPP RH. Drug treatment of lipid disorders[ J]. N Engl J Med, 1999, 341(7) :498 -511.
  • 6PAOLETTI R, FAHMY M, MAHLA G, et al. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterotaemic patients : a randomized, double-blind study [ J ]. J Cardiovasc Risk, 2001,8 ( 6 ) : 383 - 390.
  • 7DAVIDSON MH. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia [J]. Expert Opin lnvestig Drugs, 2002, 11(3) :125 -141.
  • 8DIMITROULAKOS J, NOHYNEK D, BACKWAY KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach [J]. Blood, 1999, 93(4) :1308-1318.
  • 9DUCOBU J. Hypercholesterolemia: to treat or not to treat? That is the question[J]. Rev Med Brux, 1994, 15(3) :124-131.
  • 10PARK C, LEE I, KANG WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death[ J]. Carcinogenesis, 2001, 22(10):1727- 1731

二级参考文献15

  • 1Seok SH, Park JH, Cho SA, et al. Cholesterol lowering effect of SG-GN3, the extract of salted and fermented small shrimps, Acetes japonicus, in Triton WR-1339 or high cholesterol-diet induced hyper-cholestemlemic rats [ J ]. J Ethnopharmacol, 2004,91 (2-3) :231-235.
  • 2黄泉勤.实用心血管病诊疗手册[M].北京:人民卫生出版社,1986.45-48.
  • 3刘法锦 孙冬梅.蜂蜡烷烃成分的气—质谱分析[J].中国中药杂志,1995,20(1):41-41.
  • 4广州白云山制药股份有限公司.仙立降胶囊(蜂蜡素)药效、毒理、临床研究资料汇编[C].,..
  • 5Liu YC, Liu SY, Lin MH. Effects of Psyllium on Plasma Total and Lipoprotein Cholesterol and Hepatic Cholesterol in Hamsters Fed n-3 PUFA or n -6 PUFA with High Cholesterol Levels [ J ]. Ann Nutr Metab, 2004,48 (6) :374-380.
  • 6Daley SJ,Herdefick EE,Cornhill JF, et al. Cholesterol -fed and casein -fed rabbit model of atherosclerosis [ J ]. Artenoscler Thromb, 1994,14:95-104.
  • 7Gryglewski RJ,Szczeklik A,Korbut R,et al. Themechanism of anti-thrombotic,thrombolytic and fibfinolytic actiom of camonagrel-a new synthase thromboxane inhibitor[ J ]. Wien Klin Wochenschr, 1995 ; 107 (9) :283-289.
  • 8Kjekshus J, Pedersen TR. Scandinavian Simvastatin Survival Study Gruup.Randomized trial of cholesterlol lowering in 4444 patients with coronary heart disease:the scandinavian simvastatin survival study (4s) [J]. Lancet, 1994,344 : 1383-1389.
  • 9Scott MG. Cholesterol and coronary heart disease-the 21th century[ J]. Arch Intern Med, 1997,157:1177-1184.
  • 10Inns C. Long - term results show superiority of resubastatin [ J ]. lnpharma,2001,1308 : 10-12.

共引文献8

同被引文献6

  • 1廖芳,张小娜.新型降胆固醇药物蜂蜡素胶囊[J].中国药师,2005,8(12):1039-1040. 被引量:9
  • 2DAVIDSON MH. Apolipoprotein measurements: is more wide- spread use clinically indicated? [J ]. Clin Cardiol, 2009, 32 (9) :482 -486.
  • 3BOSSOLA M, GIUNGI S, PANOCCHIA N, et al. Body mass in- dex and cardiovascular risk factors and biomarkers in hemodialysis patients[J]. J Nephrol, 2008, 21 (2) :197 -204.
  • 4SIVAKUMAR SWAMY G, RAMANARAYAN K, INAMDAR LS, et al. Triacontanol and jasmonie acid differentially modulate the lipid organization as evidenced by the fluorescent probe behavior and 31P nuclear magnetic resonance shifts in model membranes [J]. J Membr Biol, 2009, 228(3):165 -177.
  • 5SINGH DK, LI L, PORTER TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase [ J ]. J Pharmacol Exp Ther, 2006,318 ( 3 ) : 1020 - 1026.
  • 6杨丽,张小娜.蜂蜡素对HepG2细胞胆固醇生物合成的影响[J].中国药师,2008,11(10):1154-1157. 被引量:1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部